Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Berg

Showing results (451-460 of 632) with videos related to

Pageof 64
Sort By:
JHEP Reports : Innovation in Hepatology|February 3, 2025
Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studiesJinlin Hou, Thomas Berg, Arndt Vogel, et al.
Nature Communications|December 6, 2022
A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomesJawaher Alharthi, Ali Bayoumi, Khaled Thabet, et al.
JHEP Reports : Innovation in Hepatology|October 26, 2020
Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinomaJens Ricke, Ingo G Steffen, Irene Bargellini, et al.
Gut|September 9, 2016
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohortTania M Welzel, Jörg Petersen, Kerstin Herzer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 17, 2016
Apolipoprotein E allele frequencies in chronic and self-limited hepatitis C suggest a protective effect of APOE4 in the course of hepatitis C virus infectionTobias Mueller, Janett Fischer, Reinhard Gessner, et al.
JHEP Reports : Innovation in Hepatology|September 23, 2020
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD careWolf Peter Hofmann, Peter Buggisch, Lisa Schubert, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2014
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE studyThomas Berg, Pietro Andreone, Stanislas Pol, et al.
Zeitschrift Fur Gastroenterologie|January 9, 2023
Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-RegistryAndreas Geier, Monika Rau, Anita Pathil-Warth, et al.
Zeitschrift Fur Gastroenterologie|January 15, 2019
[4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]Dietrich Hüppe, Yvonne Serfert, Peter Buggisch, et al.
Open Forum Infectious Diseases|November 16, 2018
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical TrialsJason Grebely, Massimo Puoti, Heiner Wedemeyer, et al.
Pageof 64

Showing results (451-460 of 632) with videos related to

Sort By:
Pageof 64
JHEP Reports : Innovation in Hepatology|February 3, 2025
Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studiesJinlin Hou, Thomas Berg, Arndt Vogel, et al.
Nature Communications|December 6, 2022
A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomesJawaher Alharthi, Ali Bayoumi, Khaled Thabet, et al.
JHEP Reports : Innovation in Hepatology|October 26, 2020
Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinomaJens Ricke, Ingo G Steffen, Irene Bargellini, et al.
Gut|September 9, 2016
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohortTania M Welzel, Jörg Petersen, Kerstin Herzer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 17, 2016
Apolipoprotein E allele frequencies in chronic and self-limited hepatitis C suggest a protective effect of APOE4 in the course of hepatitis C virus infectionTobias Mueller, Janett Fischer, Reinhard Gessner, et al.
JHEP Reports : Innovation in Hepatology|September 23, 2020
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD careWolf Peter Hofmann, Peter Buggisch, Lisa Schubert, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2014
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE studyThomas Berg, Pietro Andreone, Stanislas Pol, et al.
Zeitschrift Fur Gastroenterologie|January 9, 2023
Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-RegistryAndreas Geier, Monika Rau, Anita Pathil-Warth, et al.
Zeitschrift Fur Gastroenterologie|January 15, 2019
[4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]Dietrich Hüppe, Yvonne Serfert, Peter Buggisch, et al.
Open Forum Infectious Diseases|November 16, 2018
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical TrialsJason Grebely, Massimo Puoti, Heiner Wedemeyer, et al.
Pageof 64